Literature DB >> 24186133

The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype.

Kyuichi Kadota1, Yi-Chen Yeh2, Camelia S Sima3, Valerie W Rusch2, Andre L Moreira4, Prasad S Adusumilli5, William D Travis4.   

Abstract

The 2011 International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) lung adenocarcinoma classification emphasizes the prognostic significance of histologic subtypes. However, one limitation of this classification is that the highest percentage of patients (∼40%) is classified as acinar predominant tumors, and these patients display a spectrum of favorable and unfavorable clinical behaviors. We investigated whether the cribriform pattern can further stratify prognosis by histologic subtype. Tumor slides from 1038 patients with stage I lung adenocarcinoma (1995-2009) were reviewed. Tumors were classified according to the IASLC/ATS/ERS classification. The percentage of cribriform pattern was recorded, and the cribriform predominant subtype was considered as a subtype for analysis. The log-rank test was used to analyze the association between histologic variables and recurrence-free probability. The 5-year recurrence-free probability for patients with cribriform predominant tumors (n=46) was 70%. The recurrence-free probability for patients with cribriform predominant tumors was significantly lower than that for patients with acinar (5-year recurrence-free probability, 87%; P=0.002) or papillary predominant tumors (83%; P=0.020) but was comparable to that for patients with micropapillary (P=0.34) or solid predominant tumors (P=0.56). The recurrence-free probability for patients with ≥10% cribriform pattern tumors (n=214) was significantly lower (5-year recurrence-free probability, 73%) than that for patients with <10% cribriform pattern tumors (n=824; 84%; P<0.001). In multivariate analysis, patients with acinar predominant tumors with ≥10% cribriform pattern remained at significantly increased risk of recurrence compared with those with <10% cribriform pattern (P=0.042). Cribriform predominant tumors should be considered a distinct subtype with a high risk of recurrence, and presence (≥10%) of the cribriform pattern is an independent predictor of recurrence, identifying a poor prognostic subset of acinar predominant tumors. Our findings highlight the important prognostic value of comprehensive histologic subtyping and recording the percentage of each histologic pattern, according to the IASLC/ATS/ERS classification with the addition of the cribriform subtype.

Entities:  

Mesh:

Year:  2013        PMID: 24186133      PMCID: PMC4374572          DOI: 10.1038/modpathol.2013.188

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  42 in total

1.  Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.

Authors:  Eunhee S Yi; Jennifer M Boland; Joseph J Maleszewski; Anja C Roden; Andre M Oliveira; Marie-Christine Aubry; Michele R Erickson-Johnson; Bolette L Caron; Yan Li; Hui Tang; Shawn Stoddard; Jason Wampfler; Kimary Kulig; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

2.  Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up.

Authors:  Jeremy St J Thomas; Gillian R Kerr; Wilma J L Jack; Fiona Campbell; Laura McKay; Hans-Christian Pedersen; Ian H Kunkler; David A Cameron; Udi Chetty; John M S Bartlett
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

3.  Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers.

Authors:  Joseph T Rabban; Rebecca S Swain; Charles J Zaloudek; Donald R Chase; Yunn Yi Chen
Journal:  Mod Pathol       Date:  2006-06-30       Impact factor: 7.842

Review 4.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

5.  Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

Authors:  Jin Ho Paik; Gheeyoung Choe; Hyojin Kim; Ji-Young Choe; Hyun Ju Lee; Choon-Taek Lee; Jong Seok Lee; Sanghoon Jheon; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

6.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

7.  Adenoid cystic carcinoma.

Authors:  Jesse Jaso; Reenu Malhotra
Journal:  Arch Pathol Lab Med       Date:  2011-04       Impact factor: 5.534

8.  Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.

Authors:  Ryu Jokoji; Takashi Yamasaki; Seigo Minami; Kiyoshi Komuta; Yasushi Sakamaki; Kengo Takeuchi; Masahiko Tsujimoto
Journal:  J Clin Pathol       Date:  2010-10-09       Impact factor: 3.411

9.  Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors.

Authors:  Julian R Molina; Marie Christine Aubry; Jean E Lewis; Jason A Wampfler; Brent A Williams; David E Midthun; Ping Yang; Stephen D Cassivi
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

10.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

View more
  45 in total

1.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

Review 2.  [The new TNM classification for lung tumors : Changes and the assessment of multiple tumor foci].

Authors:  A Harms; M Kriegsmann; L Fink; F Länger; A Warth
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

3.  Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.

Authors:  Giuseppe Pelosi; Alessio Pellegrinelli; Alessandra Fabbri; Elena Tamborini; Federica Perrone; Giulio Settanni; Adele Busico; Benedetta Picciani; Maria Adele Testi; Lucia Militti; Patrick Maisonneuve; Barbara Valeri; Angelica Sonzogni; Claudia Proto; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

4.  Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Sandra P D'Angelo; Andre L Moreira; Deborah Kuk; Camelia S Sima; Gregory J Riely; Maria E Arcila; Mark G Kris; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

5.  Histological subtypes of solitary pulmonary nodules of adenocarcinoma and their clinical relevance.

Authors:  Hui-Di Hu; Ming-Yue Wan; Chun-Hua Xu; Ping Zhan; Jue Zou; Qian-Qian Zhang; Yuan-Qing Zhang
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

6.  Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement.

Authors:  Daniel S Grosser; Haiying Zhang
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-13

7.  Cons: the confusing mucinous adenocarcinoma classification.

Authors:  Helmut H Popper
Journal:  Transl Lung Cancer Res       Date:  2017-04

8.  A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.

Authors:  Yanding Zhao; Frederick S Varn; Guoshuai Cai; Feifei Xiao; Christopher I Amos; Chao Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

9.  KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Camelia S Sima; Maria E Arcila; Cyrus Hedvat; Mark G Kris; David R Jones; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

Review 10.  Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).

Authors:  Elizabeth R Tang; Andrew M Schreiner; Bradley B Pua
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.